+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Reiter's Syndrome Treatment Market - Global Industry Size, Share, Trends, Opportunity and Forecast, 2017-2027 Segmented By Drug Type, By Dosage Form, By Route of Administration, By Distribution Channel, By End User, By Region

  • PDF Icon

    Report

  • 116 Pages
  • December 2022
  • Region: Global
  • TechSci Research
  • ID: 5636260
Free Webex Call
10% Free customization

Global Reiter's Syndrome Treatment Market is Projected to Register CAGR Growth in the Forecast Years, 2023-2027 on the Account of Growth Factors Like Increasing Instances of Reactive Arthritis, Along with the Advancement of the Treatment Processes and Methods.

Free Webex Call

Speak directly to the analyst to clarify any post sales queries you may have.

10% Free customization

This report comes with 10% free customization, enabling you to add data that meets your specific business needs.

Global Reiter’s syndrome treatment market is projected to register CAGR growth in the forecast years, 2023-2027 on the account of growth factors like increasing instances of reactive arthritis, along with the advancement of the treatment processes and methods. Moreover, advancing healthcare industry for the better availability of the patient care suffering from severe conditions like reactive arthritis, is also responsible for the growth of the global Reiter’s syndrome treatment market in the upcoming five years.

Reiter’s syndrome is also known as reactive arthritis, which is a form of inflammatory arthritis. It is the joint disease that causes painful inflammations. The disease is a reaction to a bacterial infection. These bacteria are often found in genitals like Chlamydia trachomatis or in bowel like Campylobacter, Salmonella, Shigella and Yersinia. Genital bacteria transmit through sex and usually does not show major symptoms. In certain cases, a pus-like or watery discharge from the genitals is observed. Whereas bowel bacteria usually cause diarrhea along with discharge and can be considered as minor symptoms of Reiter’s syndrome.

Increasing Instances of Reiter’s Syndrome Drives Market Growth

Rapidly increasing instances of reactive arthritis and surging demand for the effective treatment of the same in driving the growth of the global Reiter’s syndrome treatment market in the upcoming five years. Reactive arthritis is a rare form of arthritis when compared to other forms of arthritis. More than 350 million patients of arthritis are currently suffering as of 2021 in the entire world. According to CDC, In the United States, 24% of all adults, or 58.5 million people, have arthritis. 1 in every 4 adults has arthritis and reports severe joint pain.

Whereas twenty-seven per 100,000 population globally suffers from Reiter’s syndrome, that majorly affects the adult males between 20-40 years of age. Growing population, increasing instances of unprotected sexual intercourse, increase the chances of the population contracting the disease and thus aiding to the growth of the global Reiter’s syndrome treatment market in the next five years.

Market Segmentation

The global Reiter’s syndrome treatment market segmentation is based on drug type, dosage form, route of administration, distribution channel, end user, regional distribution, and competitive landscape. Drug type market segment is further fragmented into antibiotics, corticosteroids, nonsteroidal anti-inflammatory drugs (NSAIDs), immunosuppressive drugs, and others. Based on dosage form, the market is sub-segmented into tablets, injections, and others. Market segmentation on the basis of route of administration, is further bifurcated into oral, intravenous, and others. Distribution channel segment is differentiated further among retail pharmacies, hospital pharmacies, and online pharmacies. The end user segment analysis the market fragments among hospitals & clinics, ambulatory care centers, and others. The market analysis also studies the regional segmentation, divided among Asia-Pacific region, North American region, European region, South American region, and Middle East & African region.

Company Profile

F. Hoffmann-La Roche AG, Pfizer, Inc., Novartis AG, Cipla Inc., Dr. Reddy’s Laboratories Ltd., Abbott Laboratories, Inc., GlaxoSmithKline plc, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd, AstraZeneca, Plc., are enlisted in a partial list of major market players of the global Reiter’s syndrome treatment market.

Report Scope:

In this report, global Reiter’s syndrome treatment market has been segmented into following categories, in addition to the industry trends which have also been detailed below:

Reiter’s Syndrome Treatment Market, By Drug Type:

  • Antibiotics
  • Corticosteroids
  • Nonsteroidal anti-inflammatory drugs (NSAIDs)
  • Immunosuppressive Drugs
  • Others

Reiter’s Syndrome Treatment Market, By Dosage Form:

  • Tablets
  • Injections
  • Others

Reiter’s Syndrome Treatment Market, By Route of Administration:

  • Oral
  • Intravenous
  • Others

Reiter’s Syndrome Treatment Market, By Distribution Channel:

  • Retail Pharmacies
  • Hospital Pharmacies
  • Online Pharmacies

Reiter’s Syndrome Treatment Market, By End User:

  • Hospitals & Clinics
  • Ambulatory Care Centers
  • Others

Reiter’s Syndrome Treatment Market, By Region:

  • North America
  • United States
  • Mexico
  • Canada
  • Europe
  • France
  • Germany
  • United Kingdom
  • Italy
  • Spain
  • Asia-Pacific
  • China
  • India
  • Japan
  • South Korea
  • Australia
  • Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • South America
  • Brazil
  • Argentina
  • Colombia

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in global Reiter’s syndrome treatment market.

Available Customizations:

With the given market data, the publisher offers customizations according to a company’s specific needs.


This product will be delivered within 1-3 business days.

Table of Contents

1. Product Overview2. Research Methodology3. Impact of COVID-19 on Global Reiter’s Syndrome Treatment Market4. Executive Summary
5. Voice of Customer
5.1. Preference, By Drug Type
5.2. Factors Contributing to Higher Demand of Reiter’s Syndrome Treatment
5.3. Barriers to Adoption of Reiter’s Syndrome Treatment
5.4. Brand Awareness
6. Clinical Trials
6.1. Ongoing Clinical Trials
6.2. Completed Clinical Trials
6.3. Terminated Clinical Trials
6.4. Clinical Trial Analysis
7. Patent Analysis
7.1. Patent Granted (2016-2020)
7.2. Patent Applications Filed
8. Global Reiter’s Syndrome Treatment Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Drug Type (Antibiotics, Corticosteroids, Nonsteroidal anti-inflammatory drugs (NSAIDs), Immunosuppressive Drugs, Others)
8.2.2. By Dosage Form (Tablets, Injections, Others)
8.2.3. By Route of Administration (Oral, Intravenous, Others)
8.2.4. By Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Online Pharmacies)
8.2.5. By End User (Hospitals & Clinics, Ambulatory Care Centers, Others)
8.2.6. By Company (2021)
8.2.7. By Region
8.3. Product Market Map
9. North America Reiter’s Syndrome Treatment Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Drug Type
9.2.2. By Dosage Form
9.2.3. By Route of Administration
9.2.4. By Distribution Channel
9.2.5. By End User
9.2.6. By Country
9.3. North America: Country Analysis
9.3.1. United States Reiter’s Syndrome Treatment Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Drug Type
9.3.1.2.2. By Dosage Form
9.3.1.2.3. By Route of Administration
9.3.1.2.4. By Distribution Channel
9.3.1.2.5. By End User
9.3.2. Mexico Reiter’s Syndrome Treatment Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Drug Type
9.3.2.2.2. By Dosage Form
9.3.2.2.3. By Route of Administration
9.3.2.2.4. By Distribution Channel
9.3.2.2.5. By End User
9.3.3. Canada Reiter’s Syndrome Treatment Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Drug Type
9.3.3.2.2. By Dosage Form
9.3.3.2.3. By Route of Administration
9.3.3.2.4. By Distribution Channel
9.3.3.2.5. By End User
10. Europe Reiter’s Syndrome Treatment Market Outlook
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Drug Type
10.2.2. By Dosage Form
10.2.3. By Route of Administration
10.2.4. By Distribution Channel
10.2.5. By End User
10.2.6. By Country
10.3. Europe: Country Analysis
10.3.1. France Reiter’s Syndrome Treatment Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Drug Type
10.3.1.2.2. By Dosage Form
10.3.1.2.3. By Route of Administration
10.3.1.2.4. By Distribution Channel
10.3.1.2.5. By End User
10.3.2. Germany Reiter’s Syndrome Treatment Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Drug Type
10.3.2.2.2. By Dosage Form
10.3.2.2.3. By Route of Administration
10.3.2.2.4. By Distribution Channel
10.3.2.2.5. By End User
10.3.3. United Kingdom Reiter’s Syndrome Treatment Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Drug Type
10.3.3.2.2. By Dosage Form
10.3.3.2.3. By Route of Administration
10.3.3.2.4. By Distribution Channel
10.3.3.2.5. By End User
10.3.4. Italy Reiter’s Syndrome Treatment Market Outlook
10.3.4.1. Market Size & Forecast
10.3.4.1.1. By Value
10.3.4.2. Market Share & Forecast
10.3.4.2.1. By Drug Type
10.3.4.2.2. By Dosage Form
10.3.4.2.3. By Route of Administration
10.3.4.2.4. By Distribution Channel
10.3.4.2.5. By End User
10.3.5. Spain Reiter’s Syndrome Treatment Market Outlook
10.3.5.1. Market Size & Forecast
10.3.5.1.1. By Value
10.3.5.2. Market Share & Forecast
10.3.5.2.1. By Drug Type
10.3.5.2.2. By Dosage Form
10.3.5.2.3. By Route of Administration
10.3.5.2.4. By Distribution Channel
10.3.5.2.5. By End User
11. Asia-Pacific Reiter’s Syndrome Treatment Market Outlook
11.1. Market Size & Forecast
11.1.1. By Value
11.2. Market Share & Forecast
11.2.1. By Drug Type
11.2.2. By Dosage Form
11.2.3. By Route of Administration
11.2.4. By Distribution Channel
11.2.5. By End User
11.2.6. By Country
11.3. Asia-Pacific: Country Analysis
11.3.1. China Reiter’s Syndrome Treatment Market Outlook
11.3.1.1. Market Size & Forecast
11.3.1.1.1. By Value
11.3.1.2. Market Share & Forecast
11.3.1.2.1. By Drug Type
11.3.1.2.2. By Dosage Form
11.3.1.2.3. By Route of Administration
11.3.1.2.4. By Distribution Channel
11.3.1.2.5. By End User
11.3.2. India Reiter’s Syndrome Treatment Market Outlook
11.3.2.1. Market Size & Forecast
11.3.2.1.1. By Value
11.3.2.2. Market Share & Forecast
11.3.2.2.1. By Drug Type
11.3.2.2.2. By Dosage Form
11.3.2.2.3. By Route of Administration
11.3.2.2.4. By Distribution Channel
11.3.2.2.5. By End User
11.3.3. South Korea Reiter’s Syndrome Treatment Market Outlook
11.3.3.1. Market Size & Forecast
11.3.3.1.1. By Value
11.3.3.2. Market Share & Forecast
11.3.3.2.1. By Drug Type
11.3.3.2.2. By Dosage Form
11.3.3.2.3. By Route of Administration
11.3.3.2.4. By Distribution Channel
11.3.3.2.5. By End User
11.3.4. Japan Reiter’s Syndrome Treatment Market Outlook
11.3.4.1. Market Size & Forecast
11.3.4.1.1. By Value
11.3.4.2. Market Share & Forecast
11.3.4.2.1. By Drug Type
11.3.4.2.2. By Dosage Form
11.3.4.2.3. By Route of Administration
11.3.4.2.4. By Distribution Channel
11.3.4.2.5. By End User
11.3.5. Australia Reiter’s Syndrome Treatment Market Outlook
11.3.5.1. Market Size & Forecast
11.3.5.1.1. By Value
11.3.5.2. Market Share & Forecast
11.3.5.2.1. By Drug Type
11.3.5.2.2. By Dosage Form
11.3.5.2.3. By Route of Administration
11.3.5.2.4. By Distribution Channel
11.3.5.2.5. By End User
12. South America Reiter’s Syndrome Treatment Market Outlook
12.1. Market Size & Forecast
12.1.1. By Value
12.2. Market Share & Forecast
12.2.1. By Drug Type
12.2.2. By Dosage Form
12.2.3. By Route of Administration
12.2.4. By Distribution Channel
12.2.5. By End User
12.2.6. By Country
12.3. South America: Country Analysis
12.3.1. Brazil Reiter’s Syndrome Treatment Market Outlook
12.3.1.1. Market Size & Forecast
12.3.1.1.1. By Value
12.3.1.2. Market Share & Forecast
12.3.1.2.1. By Drug Type
12.3.1.2.2. By Dosage Form
12.3.1.2.3. By Route of Administration
12.3.1.2.4. By Distribution Channel
12.3.1.2.5. By End User
12.3.2. Argentina Reiter’s Syndrome Treatment Market Outlook
12.3.2.1. Market Size & Forecast
12.3.2.1.1. By Value
12.3.2.2. Market Share & Forecast
12.3.2.2.1. By Drug Type
12.3.2.2.2. By Dosage Form
12.3.2.2.3. By Route of Administration
12.3.2.2.4. By Distribution Channel
12.3.2.2.5. By End User
12.3.3. Colombia Reiter’s Syndrome Treatment Market Outlook
12.3.3.1. Market Size & Forecast
12.3.3.1.1. By Value
12.3.3.2. Market Share & Forecast
12.3.3.2.1. By Drug Type
12.3.3.2.2. By Dosage Form
12.3.3.2.3. By Route of Administration
12.3.3.2.4. By Distribution Channel
12.3.3.2.5. By End User
13. Middle East and Africa Reiter’s Syndrome Treatment Market Outlook
13.1. Market Size & Forecast
13.1.1. By Value
13.2. Market Share & Forecast
13.2.1. By Drug Type
13.2.2. By Dosage Form
13.2.3. By Route of Administration
13.2.4. By Distribution Channel
13.2.5. By End User
13.2.6. By Country
13.3. MEA: Country Analysis
13.3.1. South Africa Reiter’s Syndrome Treatment Market Outlook
13.3.1.1. Market Size & Forecast
13.3.1.1.1. By Value
13.3.1.2. Market Share & Forecast
13.3.1.2.1. By Drug Type
13.3.1.2.2. By Dosage Form
13.3.1.2.3. By Route of Administration
13.3.1.2.4. By Distribution Channel
13.3.1.2.5. By End User
13.3.2. Saudi Arabia Reiter’s Syndrome Treatment Market Outlook
13.3.2.1. Market Size & Forecast
13.3.2.1.1. By Value
13.3.2.2. Market Share & Forecast
13.3.2.2.1. By Drug Type
13.3.2.2.2. By Dosage Form
13.3.2.2.3. By Route of Administration
13.3.2.2.4. By Distribution Channel
13.3.2.2.5. By End User
13.3.3. UAE Reiter’s Syndrome Treatment Market Outlook
13.3.3.1. Market Size & Forecast
13.3.3.1.1. By Value
13.3.3.2. Market Share & Forecast
13.3.3.2.1. By Drug Type
13.3.3.2.2. By Dosage Form
13.3.3.2.3. By Route of Administration
13.3.3.2.4. By Distribution Channel
13.3.3.2.5. By End User
14. Market Dynamics
14.1. Drivers
14.2. Challenges
15. Market Trends & Developments
16. Competitive Landscape
16.1. F. Hoffmann-La Roche AG
16.2. Pfizer, Inc.
16.3. Novartis AG
16.4. Cipla Inc.
16.5. Dr. Reddy’s Laboratories Ltd.
16.6. Abbott Laboratories, Inc.
16.7. GlaxoSmithKline plc
16.8. Sun Pharmaceutical Industries Ltd
16.9. Teva Pharmaceutical Industries Ltd
16.10. AstraZeneca, Plc.
17. Strategic Recommendations18. About the Publisher & Disclaimer

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • F. Hoffmann-La Roche AG
  • Pfizer, Inc.
  • Novartis AG
  • Cipla Inc.
  • Dr. Reddy’s Laboratories Ltd.
  • Abbott Laboratories, Inc.
  • GlaxoSmithKline plc
  • Sun Pharmaceutical Industries Ltd
  • Teva Pharmaceutical Industries Ltd
  • AstraZeneca, Plc.